6/26/2025

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s websit

Source: Yahoo

6/25/2025

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days’ Retinal Vascular and Neovascular Disease Fund. […]

Source: Yahoo

6/25/2025

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

Source: Yahoo

6/25/2025

Source: SeekingAlpha

6/25/2025

Source: SeekingAlpha

6/24/2025

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

6/24/2025

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

Source: SeekingAlpha

6/24/2025

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

Source: Yahoo

6/24/2025

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days’ Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donation

Source: Yahoo

6/23/2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements. The Phase 2 COURAGE study interim readout, […]

Source: Yahoo

6/23/2025

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall Street’s expectations. The primary driver of underperformance was a steep revenue decline in the company’s retinal franchise, particularly EYLEA, which management attributed to increased competition from low-cost alternatives and reduced patient affordability due to a funding gap at co-pay assistance foundations. CEO Leonard Schleifer described the quarter as “mixed,” noting th

Source: Yahoo

6/23/2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Source: Yahoo

6/20/2025

23andMe said late Friday that TTAM Research Institute, Wojcicki’s nonprofit, was offering $305 million for the company’s assets. Last month, 23andMe said that biotech firm Regeneron had won the bidding during a bankruptcy auction to buy the company for $256 million. The bidding reopened after TTAM made its unsolicited offer.

Source: Yahoo

6/20/2025

(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.

Source: Yahoo

6/20/2025

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the company announced on Friday. The deal marks the final stage in a bidding contest that began after 23andMe filed for Chapter 11 bankruptcy in March. According to the company, TTAM will acquire substantially all of 23andMe's assets, including its Personal Genome Service, Research Services, and Lemonaid Hea

Source: Yahoo

6/20/2025

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.

Source: Yahoo

6/20/2025

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respira

Source: Yahoo

6/20/2025

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult patients with bullous pemphigoid. These statements...

Source: Finnhub

6/20/2025

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. Approval based on pivotal results showing improvements in sustained disease remission and...

Source: Finnhub

6/20/2025

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

Source: DowJones